Gaush Meditech Ltd
高视医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT
CORNEAL CONFOCAL MICROSCOPY APPROVED FOR INNOVATIVE PRODUCT REGISTRATION PROCESS

This announcement is made by Gaush Meditech Ltd (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that recently, the corneal confocal microscopy independently developed by Gaush Neotech Ltd* (高視創新科技有限公司) ("**Gaush Neotech**"), a wholly-owned subsidiary of the Company, had been reviewed and approved by Jiangsu Medical Products Administration to enter the registration process for innovative products.

Since the initial application of laser confocal microscopy in the study of living human eyeballs in 1989, the confocal microscopy has been playing an increasingly important role in the research of corneal diseases. Currently, corneal confocal microscopy has been applied to the diagnostic process and criteria for infectious keratitis. With the increasing application of refractive surgery and OK-Lens, confocal microscopy provides more assurance for early diagnosis and treatment.

In the field of ophthalmic microscopic imaging, the constraint of wide field of view and high resolution has always been the main bottleneck in microscopic observation. The corneal confocal microscopy developed by Gaush Neotech, which uses laser as the light source and utilizes tomographic confocal scanning, can clearly capture images of each layer of tissues and cells in the living cornea. With high resolution, clear images, and wider imaging field of view, it allows in-depth exploration of disease pathologies at the cellular level, thereby assisting clinical physicians in enhancing the precision and efficiency of corneal disease diagnosis.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, January 7, 2025

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* *For identification purpose only*